Lantheus Holdings Inc Dossier
Qualitative Analysis
Business overview
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a premier radiopharmaceutical-focused life sciences company dedicated to helping clinicians Find, Fight and Follow disease to deliver better patient outcomes. The company specializes in the development, manufacturing, and commercialization of innovative diagnostic and therapeutic products. Its robust commercial portfolio is anchored by three flagship products: PYLARIFY, a leading PSMA-targeted PET imaging agent for prostate cancer; DEFINITY, a widely-used ultrasound-enhancing agent for echocardiography; and Neuraceq, an amyloid PET imaging agent for Alzheimer's disease. Lantheus operates primarily through its U.S. and International segments, serving radiopharmacies, hospitals, and clinics globally.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Lantheus is sharpening its strategic focus on innovative PET radiodiagnostics in oncology and neurology, while divesting non-core legacy assets.
Expected impact: Aims to deliver sustainable, high-margin revenue growth in the mid-to-long term by prioritizing high-growth diagnostic assets.
Lantheus completed the sale of its legacy SPECT (Single-Photon Emission Computed Tomography) business to SHINE Technologies, LLC.
Expected impact: Simplifies the company's operating model and is expected to improve gross margins by approximately 200 basis points.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a provider of radiopharmaceuticals manufacturing and regulatory services to expand therapeutic pipeline capabilities and secure manufacturing infrastructure.
Financial impact: Slightly dilutive in the short term but expected to be accretive in the long run.
Acquisition of LMI and its approved F-18 PET amyloid imaging agent Neuraceq, expanding Lantheus' commercial portfolio and presence in the Alzheimer's disease diagnostic market.
Financial impact: Expected to be accretive to adjusted EPS within its first 12 months.
Strategic Partnerships
Ensures transition of the legacy SPECT business while allowing Lantheus to focus capital on high-growth PET radiodiagnostics.
Terms: Terms of the divestiture transaction completed effective January 1, 2026.